Unlocking the Full Potential of the Immune System Against Cancer

Investor Presentation

June 1, 2025

Disclaimer

This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently under way, (ii) regulatory authorities will agree with the Company's further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results and development.

For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risques") section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

transgene

Transgene in a Snapshot

Unique and highly potent viral vector-based immunotherapies

Lead program TG4050 to deliver data and create significant value in early setting solid tumors between 2025 and 2028

Additional programs and R&I activity to deliver news flow and fuel Transgene's portfolio in the mid term

myvac® – A Novel Individualized Cancer Immunotherapy Platform

MVA VECTOR BENEFITS

- Induces **broad and specific immune response** – Almost all patients treated develop a polyepitopic response*
- Excellent **safety** profile
- Proven immunogenicity in challenging immune contexture

THE RIGHT NEOANTIGENS

- Comprises **up to 30 neoantigens** selected using NEC's artificial intelligence and machine learning

Orchestrating a brighter world

NEC

INDICATION

- Targeting head and neck patients – **designed to prevent relapse**
- Only neoantigen cancer vaccine targeting this indication in adjuvant situation
- Potential to address other indications in perioperative setting

- Building upon **proof of principle** of TG4050, leading *myvac®*-based cancer vaccine: Randomized **Phase II part currently enrolling patients** based on **very promising Phase I data**
- **Potential further acceleration** based on innovation in the adjuvant setting of operable Head & Neck cancer and other early-stage indications

*Source: C. Le Tourneau, "**Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients**", ASCO - June 2025, rapid oral presentation

2025 ASCO ANNUAL MEETING

Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors

Product	Indication	Collaboration	Discovery	Phase I	Phase II	
LEAD ASSET: INDIVIDUALIZED NEOANTIGEN CANCER VACCINES (*myvac*® platform)						
TG4050 myvac	**Individualized neoantigen therapy**	**Head and neck cancer** (adjuvant)	●	R	R	**Phase I (n = 32)** - No relapse in treatment arm with at least 24 months follow up for all patients -Durable immunogenicity **Phase II (n ≃ 50)** - Completion of enrollment (Q2 2025) - Completion of randomization (Q4 2025) Orchestrating a brighter world NEC
		Other indication	●	●		Additional Ph. I trial to start (Q4 2025)
Other viral vector-based assets						
TG4001	Shared antigens cancer vaccine	Cervical and anogenital HPV+ cancers	●	●	R	Assessing potential partnership opportunities in HPV+ indications
BT-001 invirio	Oncolytic virus	Solid tumors (IT*)	●	●		Updated data expected (H2 2025) BioInvent
TG6050 invirio	Oncolytic virus	Lung cancer (IV*)	●	●		Initial data expected (Q2 2025)
Research & innovation	Internal programs		●			

**IV: intravenous administration*
IT: intratumoral administration
R: randomized

Neoantigen Therapeutic Cancer Vaccine

Focused on delivering the promise
of individualized cancer vaccine

myvac® - TG4050 | Combines Unique Know How and Expertise

MVA viral vector: a powerful platform for vaccine development



Strongly immunogenic vector

- Demonstrated capability to express **complex antigen structures** and have them presented by APCs
- Ability to elicit **strong, durable and specific** immune response
- Established safety profile

Rapid, integrated and scalable manufacturing process – Ongoing progress

transgene

myvac

one patient • one genome • one vaccine



Clinically-validated Artificial Intelligence & Bioinformatics powered approach

Neoantigen identification

- Based on multiple parameters **to identify neoantigens** from whole tumor exome analysis*
- NEC's AI and machine learning environment

NEC

Optimal neoantigen display

- **VacDesignR**® for **optimal design of the recombinant virus**
- Improve vaccine production
- Property of Transgene

AI powered and cutting-edge software environment

- Dedicated tools for TG4050 end-to-end production

Technology well suited for early setting solid tumors to prevent relapse after/with standard treatment

Click here

AACR American Association for Cancer Research

*Source: Mallone et al., "Performance of neoantigen prediction for the design of TG4050, a patient-specific neoantigen cancer vaccine", AACR, June 2020, Poster presentation

TG4050 | Operable Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy

Need to prevent or delay relapse

With currently approved treatments,
approx. 25% patients relapse
within 24 months after surgery + adjuvant therapy*

Very promising data obtained in randomized Phase I part

Compelling immunological and clinical data presented at ASCO 2025 (32 patients)

All treated patients remained disease-free after a mini. of 2 years follow-up

- ✓ **Excellent safety profile in locally advanced HPV-negative resectable SCCHN**
- ✓ **24-month DFS after treatment initiation: 100%**
- ✓ **Persistence of CD8 T cell responses over 1 year after the end of the treatment**

Ongoing Phase II part

- ➔ Completion of patient randomization: Q4 2025
- ➔ **Primary objective: 24-month DFS**

Phase I/II trial design

Approx. 80 patients
with locoregionally advanced HPV-negative SCCHN** (NCT: 04183166)

Surgery +
Adjuvant chemoradiotherapy

Complete Clinical Response
RANDOMIZATION (1:1)

myvac
TG4050
(single agent)
Repeated injections

Watchful waiting
(no treatment)

LEAD INVESTIGATOR: Pr. Christian Ottensmeier,
Clatterbridge Cancer Care Center, Liverpool

NHS The Clatterbridge Cancer Centre NHS Foundation Trust · institutCurie · INSTITUT UNIVERSITAIRE DU CANCER DE TOULOUSE Oncopole · MAYO CLINIC

* Sources: Cooper JS *et al.* NEJM, 2004; DY Lee *et al.* Head Neck, 2020
** Squamous cell carcinoma of the head and neck

***C. Le Tourneau, "**Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients**", ASCO - June 2025, rapid oral presentation

2025 ASCO ANNUAL MEETING

transgene

TG4050 | Phase I Data – Compelling Data in High-Risk Patient Population

Patient Characteristics	Arm A (N=17*) TG4050 single agent	Arm B (N=16) Watchful waiting
Male / Female, n (%)	11 (65%) / 6 (35%)	13 (81%) / 3 (19%)
Age (years), median (range)	61 (26 – 79)	57 (47 – 74)
ECOG PS 0 / 1, n (%)	12 (71%) / 5 (29%)	9 (56%) / 7 (44%)
Primary tumor location		
Oral cavity	14 (82%)	10 (63%)
Oropharynx	2 (12%)	2 (13%)
Hypopharynx	1 (6%)	3 (19%)
Larynx	-	1 (6%)
Clinical stage, n (%)		
III	7 (41%)	3 (20%)
IVa	10 (59%)	13 (81%)
Pathological stage, n (%)		
I/II	1 (6%)	1 (6%)
III	4 (24%)	3 (19%)
IVa	7 (41%)	5 (31%)
IVb	5 (29%)	7 (44%)
Concomitant cisplatin, n (%)	10 (59%)	9 (56%)

Pathological Risk Factors	Arm A (N=17*) TG4050 single agent	Arm B (N=16) Watchful waiting
Extracapsular effraction, n (%)	5 (29%)	8 (50%)
Invaded margins, n (%)	4 (24%)	3 (19%)
Perineural infiltration, n (%)	13 (77%)	7 (44%)
4+ invaded lymph nodes, n (%)	2 (12%)	3 (19%)
No. of risk factors, n (%)		
0	3 (18%)	2 (13%)
1	5 (29%)	9 (56%)
2+	9 (53%)	5 (31%)

* **17** patients evaluable for demographic and safety / **16** patients evaluable for DFS
Minimum exposure not met: the 1 patient non evaluable for DFS was diagnosed with locoregional recurrence after only 2 administrations of TG4050

Source: C. Le Tourneau, "**Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients**", ASCO - June 2025, rapid oral presentation

2025 ASCO ANNUAL MEETING

transgene

TG4050 | Phase I Data – **100% DFS 2 Years after Treatment Initiation**

Clinical Proof of Principle in Adjuvant Setting

2-year disease-free survival (DFS)



All 16 treated patients remained disease-free

Median follow-up of 30 months

3 patients in arm B (watchful waiting) **relapsed**

➜ **No related SAEs**

➜ **Good safety profile**

*Source: C. Le Tourneau, "**Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients**", ASCO - June 2025, rapid oral presentation

2025 ASCO ANNUAL MEETING

transgene

TG4050 | Phase I Data – **Persistent Specific Cellular Response Following Vaccination**

CD8 T cell responses persist over one year after the end of treatment (M24)

Arm A
TG4050 single agent at treatment start



- CD8 T cells specific to vaccine neoantigen
- CD8 T cells specific to MVA backbone
- CD8 T cells specific to unrelated viral infections (CMV, influenza)

- **Patients displayed sustained neoantigen-specific CD8+ responses against multiple selected targets**
- **Neoantigen-specific CD8 T cell responses to multiple vaccine epitopes**

Arm B
Start of TG4050 at recurrence



*Source: C. Le Tourneau, "**Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients**", ASCO - June 2025, rapid oral presentation

2025 ASCO ANNUAL MEETING

transgene

TG4050 | Potential to Extend Remission Period and Address Significant Medical Need

Head & Neck program

- **Positive Phase I part – 100% 24-month DFS**
- **Ongoing Phase II part – Last patient** to be randomized in **Q4 2025**
- **Potential acceleration** in evolving treatment landscape

myvac

one patient • one genome • one vaccine

- **Signs of clinical benefit**
- **Excellent safety profile**
- **Induces neoantigen-specific immune response**
- **Induces broad T cell response**

Expansion in other early-setting cancer indications with high risk of relapse

- **Could address other solid tumors in perioperative settings w or w/o ICIs** – Significant market opportunity
- Additional Ph. I trial to start in Q4 2025 in **new indication**

Other Viral Vector-Based Assets

Rapidly Generating Multiple Virus-Powered
Off-the-Shelf Drug Candidates Targeting Solid Tumors

Our **Oncolytic Viruses** (OV) – Combined Effects of Vector, Payload and Immune Stimulation

Compelling Clinical Data Support Intravenous (IV) Route of Administration

Cancer cell death through multiple MOAs



Virus-induced direct and specific **TUMOR ONCOLYSIS**

Antitumor activity generated by **THERAPEUTIC PAYLOADS**

Induction of **IMMUNE MECHANISMS** against tumor cells

Patented Backbone $VV_{cop}TK^{-}RR^{-}$ vector with multiple competitive advantages:

- Encode numerous and various **payloads**
- **Multiple routes of administration** (IV, IT, locoregional) and extend OV market beyond IT administration
- Potential to target multiorgan lesions and warm up TME
- Address broad range of solid tumors

invir io

Proof of principle obtained

- Good safety profile
- Able to reach tumors, selectively replicate and express payload, incl. via **intravenous administration**

Goal: to target multiorgan lesions and reverse tumor resistance

BT-001 | Promising Antitumor Activity of OV Armed with Anti-CTLA4 Ab + GM-CSF

Completed Phase I/IIa Trial Assessing IT Route of Administration

The right virus + payload

$VV_{cop}TK^{-}RR^{-}$ oncolytic armed with **BioInvent**'s potent **anti-CTLA4 Ab** + **GM-CSF**

- Activates and increases T-effector cells
- Treg depleting activity
- Stimulates immune cells (incl. APC)

Promising antitumor activity*

monotherapy and combination w. anti-PD1

- **Converts the TME from "cold" to "hot"**
- **Replicates and persists in tumor tissue**
- **Anti-CTLA4 expressed in the tumor** with **no detectable systemic exposure**
- **Partial responses in 2/6 patients** (combination regimen) & **stable disease in 4/18 patients** (monotherapy)
- **Tumor shrinkage** in injected and non-injected lesions

Completed Phase I (NCT04725331)

monotherapy and combination w. anti-PD1

- **Ph. I part B** (pembrolizumab combination) – Enrolment completed
- **Additional data expected in H2 2025**

Can be developed for multiple cancer indications

50/50 collaboration with **BioInvent**

MSD

Collaboration with MSD which provides pembrolizumab (KEYTRUDA®)

BARCELONA 2024 ESMO congress *Champiat et al, "Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors" ESMO 2024, September 14, 2024, Poster presentation

transgene

IT: intratumoral administration
TME: Tumor microenvironment

TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor

Ongoing Phase I Trial to Assess Systemic Route of Administration

Initial goal

demonstrate potential of IV administration in “cold”, non-resectable metastatic tumors

Oncolytic armed with IL-12 and anti-CTLA4 Ab

- Triggers a powerful antitumor immune response
- Restores the immune defenses within the tumor
- **Outstanding preclinical data* (strong antitumor activity)** remodeling TME (AACR 2023 and JITC, July 2024)

Phase I trial - Indication: metastatic and **PD1 failed tumors**

- Advanced or metastatic NSCLC after failure with available treatment options, including anti-PD1/PD-L1 – **Intravenous (IV) administration**
- Inclusions completed (NCT: 05788926)

- Initial data (single agent) in **Q2 2025** – Could be combined with ICIs

Potential to address a major oncology market

Journal for ImmunoTherapy of Cancer

*Azar et al, TG6050, “TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment” JITC, July 2024.

TG4001 | Phase II Trial in Patients with HPV16⁺ Cervical and Anogenital cancer

Randomized Phase II trial in patients with HPV16⁺ cervical and anogenital cancer (n=90)

incl. cervical, vulvar, vaginal, penile and anal cancers NCT: 03260023



Clinical collaboration with

MERCK

for avelumab free supply

Treated in 1st line or in 2nd line
(with a maximum of 1 prior systemic chemotherapy)

Checkpoint-blocker naïve, without liver metastasis at baseline

Including all levels of PD-L1 expression

Top line data

- **Primary objective** (improvement in progression-free survival) not met in the overall patient population
- **Positive efficacy trend in cervical cancer patients** observed in pre-planned subgroup analysis
- Assessing potential partnership opportunities in HPV+ indications

Source: C. Le Tourneau *et al.*, "**Randomized Phase II trial evaluating the combination of TG4001, an HPV16 therapeutic cancer vaccine and avelumab in patients with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer**", ASCO - June 2025, poster pres.

2025 ASCO ANNUAL MEETING

Outlook

Company Funded to Deliver Multiple Value Generating Milestones

Business funded
until the **end of April 2026**

Enables Transgene to deliver significant milestones with *myvac®* platform and other viral vector-based immunotherapies

myvac | Neoantigen vaccine – TG4050

Proof of principle

already obtained in Head and Neck cancer (adjuvant)

➔ Clinical benefit for patients and strong immunogenicity, persistent cellular immune response

Ongoing randomized Phase I/II (head and neck cancer) – 80 patients overall

➔ Ph. I part: 36-mo. follow-up data expected in **H1 2026**

➔ Ph. II part: randomization of the last patient in **Q4 2025**

Other indication

➔ Plan to launch **new Phase I** in additional indication in **Q4 2025**

Other viral vector-based assets

- **BT-001:** Phase I data presentation (**H2 2025**)
- **TG6050:** Initial Phase I data (**Q2 2025**)
- **TG4001:** Assessing potential partnership opportunities in HPV+ indications

Appendices

New Leadership to Take Transgene to the Next Level

ALESSANDRO RIVA, MD
Chairman & CEO

30+ years experience

NOVARTIS ONCOLOGY · GILEAD · ...ichnos...

CHRISTOPHE ANCEL, PharmD
VP, Chief Quality Officer and Qualified Pharmacist

MAURIZIO CEPPI, PhD
VP, Chief Scientific Officer

EMMANUELLE DOCHY, MD
VP, Medical Affairs, Chief Medical Officer

JOHN FELITTI
VP, Legal, General Counsel and Chief Compliance Officer

LUCIE LARGUIER
VP, Chief Financial Officer

CHRISTELLE SCHWOERER
VP, Human Resources

SIMONE STEINER
VP, Chief Technical Officer

JAMES WENTWORTH
VP, Chief Business Officer

TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities

Combines Bioengineering and Digital Transformation



Sequencing Lab

Orchestrating a brighter world NEC

transgene

TG4050 | Phase I data – Promising Signals of Clinical Activity in Adjuvant Setting

Head & Neck Cancer Trial

32 patients randomized (R) – As of April 2025



All 16 treated patients remained disease-free

Only patients in the control arm relapsed

DFS : 100% vs 81% after 2 years of follow-up

*Adapted from: C. Le Tourneau, "**Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients**", ASCO - June 2025, rapid oral presentation

2025 ASCO ANNUAL MEETING

transgene

TG4050 | Phase I data – Generates and/or Expands Tumor Specific T Cells

Number of positive responses per patient (Elispot assay)
Head and Neck Cancer (Phase I part)



*Immunoreactive T-cells detected at baseline but not amplified post treatment

Despite low mutational burden, **immunogenic targets could be selected for all patients**

Neoantigen-specific T-cell responses were detected

***De novo* responses were detected in a majority of patients**

Source: G. Le Tourneau *et al.*, "**Randomized Phase I Trial of Adjuvant Individualized TG4050 Vaccine in Patients with Locally Advanced Resected HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)**", SITC November 2024, Poster presentation

NB: analysis based on research assay; independent GCLP-like analysis to be conducted

Exploration of Tumor TME

TME: tumor micro-environment, TMB: tumor mutational burden, F: fibrotic, NF: non-fibrotic

Challenging population with high prevalence of **low/negative PD-L1 expressors** and **relatively poor pro-immune infiltrates**

Arm A: TG4050 single agent

PD-L1	TMB (mt/Mb)	TME functional class	Tumor cell proliferation
Medium	3.19	Immune Desert	Medium
Medium	1.99	Immune Desert	Low
Medium	4.34	Imm. Enriched, NF	Medium
Low	3.28	Immune Desert	Medium
Medium	3.42	Immune Desert	Medium
Medium	1.9	Imm. Enriched, NF	Low
Medium	3.16	Fibrotic	Medium
Low	4.2	Immune Desert	Medium
Medium	1.99	Imm. Enriched, F	Low
Medium	4	Imm. Enriched, NF	Low
High	1.37	Imm. Enriched, NF	Medium
Low	2.41	Immune Desert	High
Low	3.05	Immune Desert	Medium
Medium	7.7	Imm. Enriched, F	Medium
Medium	1.68	Imm. Enriched, NF	Medium
Medium	1.46	Immune Desert	Low

Arm B: Control arm

PD-L1	TMB (mt/Mb)	TME functional class	Tumor cell proliferation
Medium	3.02	Immune Desert	Medium
Medium	1.6	Immune Desert	Medium
Low	4.26	Immune Desert	Medium
Medium	3.02	Immune Desert	Medium
Medium	3.36	Immune Desert	Medium
High	3.28	Imm. Enriched, NF	High
Low	3.64	Immune Desert	Medium
Medium	7.95	Fibrotic	Low
Medium	1.9	Immune Desert	Medium
Medium	0.34	Immune Desert	Medium
Medium	2.77	Immune Desert	Medium
Medium	5.24	Immune Desert	Low
Medium	2.91	Imm. Enriched, NF	Medium
Medium	0.03	Imm. Enriched, NF	Medium
Low	2.1	Immune Desert	Medium
Medium	3.56	Immune Desert	Medium

Source: G. Le Tourneau *et al.*, "**Randomized Phase I Trial of Adjuvant Individualized TG4050 Vaccine in Patients with Locally Advanced Resected HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)**", SITC November 2024, Poster presentation

Environmental, Social and Governance Commitments

Transgene's **ESG** strategy is based on 6 commitments

- To **patients**
- To our **partners**
- To our **employees**
- To our **shareholders** and **investors**
- To **society** and the **regions**
- To the **planet**

44/100
Vigeo Eiris (+20 pts)

85/100
Gaïa EthiFinance Award (+8 pts)

99/100
Equal Employment Index (+4 pts)

TOP 5 French companies with the **best ESG performance** for 2023*.

ESG rating
higher than industry benchmark (Pharma/Biotech)

Our ESG policy is detailed in the chap. 4 in the URD 2024

URD 2024

*with < *250 employees*, according to the Gaia EthiFinance 2024 Award study
LinkedIn / Website

Study

CONTACT

Lucie Larguier

Chief Financial Officer

investorrelations@transgene.fr

400 Boulevard Gonthier d'Andernach | Parc d'Innovation | CS80166
67405 Illkirch Graffenstaden Cedex | France
Tél.: + 33 (0)3 88 27 91 21 | **www.transgene.fr**